文献速递系统性红斑狼疮

SGLT2抑制剂达格列净在系统性红斑狼疮患者中的安全性与疗效:一项I/II期试验

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.
PubMed 文献 · RMD Open · 2022-01-01

这项单臂、开放标签、研究者发起的I/II期试验纳入38例中国系统性红斑狼疮(SLE)患者(伴或不伴狼疮肾炎),在标准治疗基础上加用达格列净10 mg每日口服6个月,主要终点为安全性。结果显示安全性可接受,但SLE疾病活动指数评分和蛋白尿未见改善,狼疮 flare 累积发生率为18%,泼尼松剂量降低约30%。

要点

  • 38例SLE患者中记录19例(50%)不良事件,8例(21%)导致停药,其中4例(10.5%)归因于达格列净。
  • 2例严重不良事件(1例主要狼疮 flare、1例真菌性肺炎),下尿路感染1例(2.63%)。
  • SLE疾病活动指数评分及狼疮肾炎患者(17例)蛋白尿未见改善,泼尼松剂量降低约30%。

核心结论

  • 达格列净在成人SLE患者中具有可接受的安全性。
  • 其可能的肾脏/心脏保护作用及长期安全性问题,尤其在SLE患者、特别是狼疮肾炎患者中,有待进一步探索。

研究设计与样本

  • 单臂、开放标签、研究者发起的I/II期试验,纳入38例中国SLE患者(伴或不伴狼疮肾炎)。
  • 患者在标准治疗基础上口服达格列净10 mg每日一次,持续6个月;主要终点为安全性,次要疗效终点为疾病活动的复合评估。
  • 试验注册号:ChiCTR1800015030。

主要发现

  • 共记录19例(50%)不良事件,其中8例(21%)导致停药,4例(10.5%)归因于达格列净。
  • 记录2例严重不良事件(1例主要狼疮 flare、1例真菌性肺炎);下尿路感染见于1例(2.63%)患者。
  • 次要终点显示SLE疾病活动指数评分或蛋白尿(17例狼疮肾炎患者中)未见改善;狼疮 flare 累积发生率为18%,泼尼松剂量降低约30%。
  • 观察到体重指数净变化-0.50 kg/m2、收缩压净变化-3.94 mm Hg、血红蛋白水平净变化+8.26 g/L。
  • 总体估算肾小球滤过率(eGFR)保持稳定,基线eGFR <90 mL/min/1.73 m2的狼疮肾炎患者中eGFR斜率有改善。

关键数值与推荐

  • 达格列净用法:口服10 mg每日一次,加于标准治疗,持续6个月。
  • 主要安全性结果:不良事件19例(50%),导致停药8例(21%),归因于达格列净4例(10.5%)。
  • 严重不良事件2例(主要狼疮 flare 1例、真菌性肺炎1例);下尿路感染1例(2.63%)。
  • 疗效结果:SLE疾病活动指数评分或蛋白尿(17例狼疮肾炎患者)未见改善;狼疮 flare 累积发生率18%;泼尼松剂量降低约30%。
  • 其他变化:体重指数-0.50 kg/m2、收缩压-3.94 mm Hg、血红蛋白+8.26 g/L;总体eGFR稳定,基线eGFR <90 mL/min/1.73 m2的狼疮肾炎患者eGFR斜率有改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,达格列净在SLE患者中可能的肾脏/心脏保护作用及长期安全性问题,尤其在SLE患者、特别是狼疮肾炎患者中,有待进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium-glucose cotransporter-2 inhibitors have been identified profound renal/cardiac protective effects in different diseases. Here, we assessed the safety and efficacy of dapagliflozin among adult patients with systemic lupus erythematosus (SLE). METHODS: We conducted a single-arm, open-label, investigator-initiated phase I/II trial of dapagliflozin in Chinese patients with SLE with/without lupus nephritis (LN). Patients received oral dapagliflozin at a daily dose of 10 mg added to the standard of care for 6 months. The primary end point was the safety profile. The secondary efficacy end points were composite assessments of disease activity. RESULTS: A total of 38 eligible patients were enrolled. Overall, 19 (50%) adverse events (AEs) were recorded, including 8 (21%) AEs leading to drug discontinuation, of which 4 (10.5%) were attributed to dapagliflozin. Two serious AEs (one of major lupus flare and one of fungal pneumonia) were recorded. Lower urinary tract infection was observed in one (2.63%) patient. The secondary end points revealed no improvement of SLE Disease Activity Index scores or proteinuria (among 17 patients with LN); the cumulative lupus flare rate was 18%, and a reduction of ~30% in the prednisone dose was captured. Net changes in body mass index (-0.50 kg/m2), systolic blood pressure (-3.94 mm Hg) and haemoglobin levels (+8.26 g/L) were detected. The overall estimated glomerular filtration rate (eGFR) was stable, and there was an improvement in the eGFR slope among patients with LN with a baseline eGFR <90 mL/min/1.73 m2. CONCLUSION: Dapagliflozin had an acceptable safety profile in adult patients with SLE. Its possible renal/cardiac protective effects and long-term safety issues in patients with SLE, patients with LN in particular, call for further exploration. TRIAL REGISTRATION NUMBER: ChiCTR1800015030.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Wang H, Li T, Sun F, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open. 2022. PMID: 36288823. doi:10.1136/rmdopen-2022-002686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。